EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Design, synthesis and biological evaluation of new 2,6-difluorinated phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonates as new antimicrotubule agents

Chahrazed Bouzriba, Mathieu Gagné-Boulet, Atziri Corin Chavez Alvarez, Vincent Ouellette, Isabelle Laverdière, Sébastien Fortin

Bioorganic Chemistry · 2024

DOI: 10.1016/j.bioorg.2024.107299 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic Chemistry, 2024. Verfasst von Chahrazed Bouzriba und 5 weiteren Autor:innen. Beteiligte Einrichtung: Centre de recherche du CHU de Québec-Université Laval, Axe oncologie, Québec, QC, Canada; Faculté de pharmacie, Université Laval, Pavillon Ferdinand-…. Hauptthemen laut MEDLINE: Neoplasms, Antineoplastic Agents. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Canada Foundation for Innovation, Natural Sciences and Engineering Research Council of Canada, Fonds de recherche du Québec Santé.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We previously discovered a novel family of antimicrotubule agents designated as phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonates (PIB-SOs). In this study, we evaluated the effect of the difluorination of the aromatic ring bearing the imidazolidin-2-one moiety (ring A) at positions 3, 5 and 2, 6 on their antiproliferative activity on four cancer cell lines, their ability to disrupt the microtubules and their toxicity toward chick embryos. We thus synthesized, characterized and biologically evaluated 24 new difluorinated PIB-SO derivatives designated as phenyl 3,5-difluoro-4-(2-oxoimidazolidin-1-yl)benzenesulfonates (3,5-PFB-SOs, 4-15) and phenyl 2,6-difluoro-4-(2-oxoimidazolidin-1-yl)benzenesulfonates (2,6-PFB-SOs, 16-27). The concentration of the drug required to inhibit cell growth by 50% (IC50) of 3,5-PFB-SOs is over 1000 nM while most of 2,6-PFB-SOs exhibit IC50 in the nanomolar range (23-900 nM). Furthermore, the most potent 2,6-PFB-SOs 19, 26 and 27 arrest the cell cycle progression in G2/M phase, induce cytoskeleton disruption and impair microtubule polymerization. Docking studies also show that the most potent 2,6-PFB-SOs 19, 21, 24, 26 and 27 have binding affinity toward the colchicine-binding site (C-BS). Moreover, their antiproliferative activity is not affected by antimicrotubule- and multidrug-resistant cell lines. Besides, they exhibit improved in vitro hepatic stability in the mouse, rat and human microsomes compared to their non-fluorinated counterparts. They also showed theoretical pharmacokinetic, physicochemical and drug-like properties suited for further in vivo assays. In addition, they exhibit low to no systemic toxicity toward chick embryos. Finally, our study evidences that PIB-SOs must be fluorinated in specific positions on ring A to maintain both their antiproliferative activity and their biological activity toward microtubules.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsAntineoplastic AgentsChick EmbryoHumansRatsMiceAnimalsBenzenesulfonatesColchicineCell ProliferationBinding SitesDrug Screening Assays, AntitumorStructure-Activity RelationshipTubulinCell Line, TumorTubulin Modulators

Stichwörter der Autor:innen

26-PFB-SOs6-difluoro-4-(2-oxoimidazolidin-1-yl)benzenesulfonatesAnticancer agentsAntimicrotubule agentsFluorinationPIB-SOsPhenyl 2Phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonates

Substanzen

BenzenesulfonatesColchicineAntineoplastic AgentsTubulinTubulin Modulators

Autor:innen und Institutionen

  • Centre de recherche du CHU de Québec-Université Laval, Axe oncologie, Québec, QC, Canada; Faculté de pharmacie, Université Laval, Pavillon Ferdinand-Vandry, 1050 avenue de la Médecine, Québec QC G1V 0A6, Canada; These a…
  • Centre de recherche du CHU de Québec-Université Laval, Axe oncologie, Québec, QC, Canada; Faculté de pharmacie, Université Laval, Pavillon Ferdinand-Vandry, 1050 avenue de la Médecine, Québec QC G1V 0A6, Canada; Centre…
  • Centre de recherche du CHU de Québec-Université Laval, Axe oncologie, Québec, QC, Canada; Faculté de pharmacie, Université Laval, Pavillon Ferdinand-Vandry, 1050 avenue de la Médecine, Québec QC G1V 0A6, Canada.
  • Centre de recherche du CHU de Québec-Université Laval, Axe oncologie, Québec, QC, Canada; Faculté de pharmacie, Université Laval, Pavillon Ferdinand-Vandry, 1050 avenue de la Médecine, Québec QC G1V 0A6, Canada. Electro…

Förderung

  • Canada Foundation for Innovation
  • Natural Sciences and Engineering Research Council of Canada
  • Fonds de recherche du Québec Santé

Zitieren

APA

Bouzriba, C., Gagné-Boulet, M., Chavez Alvarez, A. C., Ouellette, V., Laverdière, I., & Fortin, S. (2024). Design, synthesis and biological evaluation of new 2,6-difluorinated phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonates as new antimicrotubule agents. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2024.107299

Vancouver

Bouzriba C, Gagné-Boulet M, Chavez Alvarez AC, Ouellette V, Laverdière I, Fortin S. Design, synthesis and biological evaluation of new 2,6-difluorinated phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonates as new antimicrotubule agents. Bioorganic Chemistry. 2024. doi:10.1016/j.bioorg.2024.107299

BibTeX
@article{Bouzriba2024,
  author = {Bouzriba, Chahrazed and Gagné-Boulet, Mathieu and Chavez Alvarez, Atziri Corin and Ouellette, Vincent and Laverdière, Isabelle and Fortin, Sébastien},
  title = {Design, synthesis and biological evaluation of new 2,6-difluorinated phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonates as new antimicrotubule agents},
  journal = {Bioorganic Chemistry},
  year = {2024},
  doi = {10.1016/j.bioorg.2024.107299}
}
Kostenlos starten →